Loading…
Johnson Pharmacare (BSE 532154)₹0.46000.00%Diversified Commercial Services
In the Mar 2026 quarter (standalone), Johnson Pharmacare reported sales of ₹0 Cr and net profit of −₹56.03 Cr. For the year to Mar 2026, sales were ₹0 Cr and net profit −₹56.03 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 0.00 | 0.00 |
| Expenses | 0.00 | 43.14 |
| Operating Profit | 0.00 | −42.97 |
| Other Income | 0.00 | −12.98 |
| Interest | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 |
| Profit before tax | −0.99 | −55.95 |
| Tax % | 0.0% | 0.0% |
| Exceptional items | 0.00 | −13.95 |
| Net Profit | −1.01 | −56.03 |
| EPS (Rs) | 0.00 | −1.00 |
| Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 0.99 | 0.99 | 2.99 | 2.99 | 0.00 | 0.00 |
| Expenses | 1.01 | 1.01 | 3.01 | 2.01 | 0.00 | 43.14 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −42.97 |
| OPM % | −1.1% | 0.0% | 4.0% | 9.1% | — | — |
| Other Income | 0.00 | 0.00 | 0.00 | −1.99 | 0.00 | −12.98 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 0.00 | −0.99 | −0.99 | −55.95 |
| Tax % | 0.0% | — | 31.0% | −3.0% | 0.0% | 0.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | −1.99 | 0.00 | −13.95 |
| Net Profit | 0.00 | 0.00 | 0.00 | −0.99 | −1.01 | −56.03 |
| EPS (Rs) | 0.00 | 0.00 | 0.00 | −0.01 | 0.00 | −1.00 |
| Dividend payout % | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 50.06 | 50.02 | 50.04 | 50.00 | 50.06 | 50.05 | 50.06 | 55.03 | 55.05 | 55.06 | 55.06 | 54.91 |
| Reserves | 8.01 | 8.00 | 8.02 | 8.01 | 8.02 | 8.02 | 8.01 | 3.00 | 2.01 | 2.00 | 1.00 | −55.00 |
| Borrowings | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 1.01 | 21.09 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 |
| Total Liabilities | 60.08 | 59.03 | 59.07 | 60.02 | 60.09 | 59.08 | 59.09 | 60.05 | 60.08 | 60.08 | 58.08 | 22.00 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 54.07 | 43.04 | 54.06 | 54.03 | 53.08 | 52.07 | 52.08 | 54.06 | 46.07 | 46.09 | 42.07 | 20.01 |
| Other Assets | 6.01 | 15.99 | 5.01 | 5.99 | 7.01 | 7.01 | 7.01 | 5.99 | 14.01 | 13.99 | 16.01 | 1.99 |
| Trade receivables | 0.44 | 12.61 | 0.00 | 0.00 | 0.93 | 0.93 | 1.69 | 1.06 | 0.00 | 0.00 | 0.00 | 2.24 |
| Cash & equivalents | 0.26 | 0.33 | 0.33 | 0.32 | 0.29 | 0.27 | 0.22 | 0.03 | 0.00 | 0.00 | 0.00 | 0.07 |
| Total Assets | 60.08 | 59.03 | 59.07 | 60.02 | 60.09 | 59.08 | 59.09 | 60.05 | 60.08 | 60.08 | 58.08 | 22.00 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 8.01 | −11.02 | 11.01 | −1.01 | −1.01 | 0.00 | 5.01 | 0.00 | −2.01 | −57.08 |
| Cash from investing activity | 9.99 | 10.98 | −10.99 | 0.00 | 0.99 | 0.99 | −4.99 | −0.99 | 2.99 | 57.95 |
| Cash from financing activity | 1.99 | 0.00 | 0.00 | 1.01 | 0.00 | −0.99 | 0.00 | 1.01 | −0.99 | 0.00 |
| Net cash flow | 21.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capex | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free cash flow | 8.01 | −10.99 | 11.01 | −1.01 | −0.99 | 0.00 | 4.99 | 0.00 | −2.01 | −57.03 |
| CFO / OP % | −41,350.0% | 8,385.1% | −8,199.9% | 1,417.1% | 9,300.1% | −188.9% | 3,800.1% | −200.0% | 764.1% | 134.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | — | — | — | — | 365 | — | 807 | 118 | 0 | — | — | — |
| Inventory days | — | — | — | — | — | — | 0 | 0 | 0 | — | — | — |
| Cash conversion cycle | — | — | — | — | 365 | — | 807 | 118 | 0 | — | — | — |
| Working capital days | — | — | — | — | 1,931 | — | 2,266 | −10 | −142 | — | — | — |
| ROCE % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | −104.9% |
For the Mar 2026 quarter, Johnson Pharmacare reported sales of ₹0 Cr and net profit of −₹56.03 Cr.
Johnson Pharmacare's sales for the year to Mar 2026 were ₹0 Cr.
Net profit for the year to Mar 2026 was −₹56.03 Cr. Earnings per share over the same trailing period were ₹−1.00.
Johnson Pharmacare reported borrowings of ₹21.09 Cr at Mar 2026, against cash and equivalents of ₹0.07 Cr.
Cash from operations was −₹57.08 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹57.03 Cr.